Taiwan Stem Cell Therapeutics (TSCT) works alongside some of Taiwan’s leading medical researchers and institutions in the regenerative medical space to develop stem-cell treatments primarily targeted at neurological disorders.
In 2020, Taiwan's government identified the Precision Medicine Initiative as a core strategic industry, with regenerative medicine as a key focus. Taiwan's leadership in regenerative medicine is attributed to a robust biotechnology industry, favorable regulatory environment, and investment in research and development. These resources provide a wealth of talent, cost-competitive R&D, and manufacturing, supported by one of the world's top-rated public health systems.
TSCT與臺灣再生醫學領域的一些領先醫學研究人員和機构合作,開發主要針對神經疾病的幹細胞治療方法。
2020年,臺灣政府把Taiwan Precision Medicine Initiative (TPMI)確定為覈心戰畧產業,再生醫學是其中一個重點。 臺灣在再生醫學方面的領先地位歸功於强大的生物技術產業、有利的監管環境以及研發投資。 這些資源提供了豐富的人才、具有成本競爭力的研發和製造,並得到了世界頂級公共衛生系統之一的支持。
TSCT's beginnings are rooted in the personal experiences of its Chairman - Joseph S. Chiang and his personal struggles with Parkinson's Disease. Despite seeing multiple doctors and trying various western and eastern treatments for Parkinson's disease, Joseph did not see his symptoms improve. Instead, his condition worsened to the point where he was unable to walk independently, and unable to perform many basic daily tasks independently.
Seeking an alternative approach, Mr. Chiang turned to the research and medical team behind TSCT's technology, where he received a personalized treatment plan anchored by Stem Cell Treatments. After one 12-month treatment cycle, Mr. Chiang regained his independence and regained his quality of life, allowing him to travel and play golf once again. TSCT's focus on developing treatments for degenerative neurological conditions stems from firsthand experience with these challenges and the desire to help others restore their quality of life. The research team behind TSCT's technology has driven innovation on this intersection of Stem Cell Therapy and Neurological disorders for over 20 years, publishing over 700 papers and being recognized globally for their leadership in the space.
TSCT的起步源於其主席蔣行的個人經歷以及他與帕金森病的個人鬥爭。 儘管看了多位醫生,並嘗試了各種西方和東方的帕金森病治療方法,約瑟夫的症狀並沒有改善。 相反,他的病情惡化到無法獨立行走,也無法獨立完成許多基本的日常任務。
為了尋求另一種方法,蔣先生求助於TSCT科技背後的研究和醫療團隊,在那裡他得到了一個以幹細胞治療為基礎的個性化治療計畫。 經過一個12個月的治療週期,蔣先生恢復了獨立,恢復了生活質量,可以再次旅行和打高爾夫球。 TSCT專注於開發退行性神經疾病的治療方法,源於對這些挑戰的第一手經驗,以及幫助他人恢復生活質量的願望。 20多年來,TSCT科技背後的研究團隊一直在推動幹細胞治療和神經疾病交叉領域的創新,發表了700多篇論文,並因其在該領域的領導地位而受到全球認可。
Copyright © 2024 Taiwan Stem Cell Therapeutics — 保留所有權利。